Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

    Recruiting

    4 1 1 1
    Austria Belgium France The Netherlands Spain Sweden
  • Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

    Recruiting

    2 1 1
    Investigated Drugs:
    Belgium France
  • Study on the Safety and Effectiveness of MB-CART2019.1, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory B Cell Neoplasms

    Recruiting

    2 1 1 1
    France Germany Italy The Netherlands
  • Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

    Recruiting

    2 1 1 1
    Austria Belgium Croatia Czechia Finland France +9
  • Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

    Recruiting

    1 1 1
    Germany
  • Study on UCART20x22 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Using a Drug Combination

    Recruiting

    2 1 1 1
    France Italy Spain
  • Study of MEN1703 and Glofitamab for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

    Recruiting

    2 1 1 1 1
    France Poland Spain
  • Efficacy of KITE-753 Compared with Axicabtagene Ciloleucel in Adults with Relapsed or Refractory Large B‑Cell Lymphoma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia France Italy The Netherlands Spain
  • A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers

    Not yet recruiting

    1 1 1
    Investigated Drugs:
    The Netherlands
  • Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    Not yet recruiting

    2 1 1 1
    Croatia Hungary